reports
Garden Veggie Snacks™ Revamps Products With Avocado Oil, a NEW Fourth ...
Garden Veggie Snacks™ Revamps Products With Avocado Oil, a NEW Fourth Veggie Straw, Enhanced Real Cheese Flavors, and Bold New Packaging The New Portfolio of Better-for-You Snacks Parents Trust and Kids Love, Now at Target® HOBOKEN, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Garden Veggie Snacks™, the pioneer in better-for-you snacking and The Original Veggie Straws™, today announced the boldest reinvention in its history. Garden Veggie Straws® and Garden Veggie™ Puffs are now made with avocado oil, bringing forward the flavors kids crave and the quality parents can feel good about. The...
Hain Celestial Reports Fiscal Fourth Quarter and Fiscal Year 2025 Fina...
Hain Celestial Reports Fiscal Fourth Quarter and Fiscal Year 2025 Financial Results HOBOKEN, N.J., Sept. 15, 2025 (GLOBE NEWSWIRE) -- The Hain Celestial Group, Inc. (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, today reported financial results for its fiscal fourth quarter and fiscal year ended June 30, 2025. "We are taking decisive action to optimize cash, deleverage our balance sheet, stabilize sales, and improve profitability as we recognize our performance has not met expectations,” said Alison...
Earth’s Best® Reinforces Industry Leadership with Infant Formula Certi...
Earth’s Best® Reinforces Industry Leadership with Infant Formula Certifications for Purity, Safety and Quality Brand Achieves Clean Label Project Awards and Recognized by BabyCenter,What to Expect and Consumer Reports for Excellence in Organic Infant Nutrition HOBOKEN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Earth's Best®, a pioneer in organic baby food and trusted partner to parents and caregivers to provide the nutrition little ones need from birth to backpack, is proud to announce several new achievements for leadership in organic nutrition. Most recently, the brand achieved Purit...
Dexcom Inc: 1 director
A director at Dexcom Inc sold 4,824 shares at 74.170USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
Hain Celestial Announces Fiscal 2025 Fourth Quarter and Full Year Resu...
Hain Celestial Announces Fiscal 2025 Fourth Quarter and Full Year Results Conference Call and Webcast HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Hain Celestial Group (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, will release its fiscal fourth quarter and full year financial results before the market opens on Monday, September 15, 2025, as the company is now an accelerated filer under Securities and Exchange Commission rules. The company will host a conference call, which will be webcast, to di...
- Research Team ACF
KDST + NLSP Combined Core Investment Case 29052025
We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TDOC TELADOC HEALTH INC.
PODD INSULET CORPORATION
ORMP ORAMED PHARMACEUTICALS
MDT MEDTRONIC PLC
LLY ELI LILLY AND COMPANY
SAN SANOFI
TILS TIZIANA LIFE SCIENCES
CRSP CRISPR THERAPEUTICS AG
SENS SENSEONICS HOLDINGS
TNDM TANDEM DIABETES CARE
NOVO NOVO NORDISK A/S-B
SANA SANA BIOTECHNOLOGY
HIMS HIMS AND HERS HEALTH INC (A)
KDST.TA:TASE KADIMASTEM
NLSP:NasdaqCM NLS PHARMACEUTICS
CRSP (NASDAQ) CRISPR THERAPEUTICS
TLSA TIZIANA LIFE SCIENCES LTD
- Dave Nicoski
- Ross LaDuke
DXCM DEXCOM INC.
XRAY DENTSPLY SIRONA INC.
WING WINGSTOP INC.
VRTS VIRTUS INVESTMENT PARTNERS INC.
UHS UNIVERSAL HEALTH SERVICES INC. CLASS B
STKS ONE GROUP HOSPITALITY
SNPS SYNOPSYS INC.
SMG SCOTTS MIRACLE-GRO COMPANY CLASS A
SFST SOUTHERN FIRST BANCSHARES
RGNX REGENXBIO INC.
RCKY ROCKY BRANDS
PRGO PERRIGO CO. PLC
MPWR MONOLITHIC POWER SYSTEMS INC.
JRVR JAMES RIVER GROUP HOLDINGS LTD
IRM IRON MOUNTAIN INC.
GPC GENUINE PARTS COMPANY
GD GENERAL DYNAMICS CORPORATION
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CROX CROCS INC.
CAL CALERES INC.
BKE BUCKLE INC.
ASC ARDMORE SHIPPING
AMOT ALLIED MOTION TECHNOLOGIES
ACAD ACADIA PHARMACEUTICALS INC.
SBL SAFE BULKERS INC.
LPG DORIAN LPG
MEG. MEG ENERGY CORP.
MDU MDU RESOURCES GROUP INC
NAT NORDIC AMERICAN TANKERS LIMITED
EVTC EVERTEC INC.
FSLR FIRST SOLAR INC.
IONS IONIS PHARMACEUTICALS INC.
NMIH NMI HOLDINGS INC. CLASS A
AGYS AGILYSYS INC.
SJM J.M. SMUCKER COMPANY
FIZZ NATIONAL BEVERAGE CORP.
NHC NATIONAL HEALTHCARE CORP.
INSW INTERNATIONAL SEAWAYS INC.
FLGT FULGENT GENETICS
DK DELEK US HOLDINGS INC
CELH CELSIUS HOLDINGS INC.
AMD ADVANCED MICRO DEVICES INC.
TTEC TTEC HOLDINGS INC.
AVGO BROADCOM INC.
ST SENSATA TECHNOLOGIES HOLDING PLC
ELAN ELANCO ANIMAL HEALTH INC.
MEC MAYVILLE ENGINEERING
DELL DELL TECHNOLOGIES INC CLASS C
CSTM CONSTELLIUM SE CLASS A
OI O-I GLASS INC
BWMN BOWMAN CONSULTING GROUP LTD
DINO HOLLYFRONTIER CORP
EVEX EVE HOLDING INC
SPXC SPX TECHNOLOGIES INC
WEST WESTROCK COFFEE COMPANY LLC
ADCT ADC THERAPEUTICS SA
SVV SAVERS VALUE VILLAGE INC
GUTS FRACTYL HEALTH INC
AGEN AGENUS INC.
ARDT ARDENT HEALTH PARTNERS INC
PCT PROVIDENT CAP TR II SKIS 8.75%29
MKTW MARKETWISE INC
Hain Celestial Reports Fiscal Third Quarter 2025 Financial Results
Hain Celestial Reports Fiscal Third Quarter 2025 Financial Results HOBOKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- The Hain Celestial Group, Inc. (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, today reported financial results for its fiscal third quarter ended March 31, 2025. In a separate release today, the Company announced a CEO transition and strategic review of the Company’s portfolio. "We are disappointed with our third quarter results, which fell far short of our expectations primarily due t...
The Hain Celestial Group Announces CEO Transition and Strategic Review...
The Hain Celestial Group Announces CEO Transition and Strategic Review of Portfolio Appoints Board Member and Global Consumer Goods Veteran Alison E. Lewis as Interim CEO HOBOKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- The Hain Celestial Group, Inc. (Nasdaq: HAIN) (“Hain,” or the “Company”), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, announced today that Wendy Davidson is departing as President, Chief Executive Officer and as a member of the Board of Directors (the “Board”), effective this morning. The Hain B...
Hain Celestial Announces Fiscal Third Quarter 2025 Results Conference ...
Hain Celestial Announces Fiscal Third Quarter 2025 Results Conference Call and Webcast HOBOKEN, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Hain Celestial Group (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, plans to issue its financial results for the fiscal third quarter before the market opens on Wednesday, May 7, 2025. The company will host a conference call, which will be webcast, to discuss the results at 8:00 AM ET. Speaking on behalf of Hain Celestial will be Wendy Davidson, President and Chief ...
Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medi...
EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East." The report surveyed over 2,500 people, made up of individuals with Type 2 diabetes and healthcare professionals, from Germany, Italy, the Netherlands, Saudi Arabia, Spain and the United Kingdom. The findings provide valuable insights into access to care and perceptions of diabetes technology. During the conference, first-ever accuracy a...
- Research Team ACF
ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...
Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TDOC TELADOC HEALTH INC.
PODD INSULET CORPORATION
ORMP ORAMED PHARMACEUTICALS
MDT MEDTRONIC PLC
LLY ELI LILLY AND COMPANY
SAN SANOFI
TILS TIZIANA LIFE SCIENCES
CRSP CRISPR THERAPEUTICS AG
SENS SENSEONICS HOLDINGS
TNDM TANDEM DIABETES CARE
NOVO NOVO NORDISK A/S-B
SANA SANA BIOTECHNOLOGY
HIMS HIMS AND HERS HEALTH INC (A)
KDST.TA:TASE KADIMASTEM
NLSP:NasdaqCM NLS PHARMACEUTICS
CRSP (NASDAQ) CRISPR THERAPEUTICS
TLSA TIZIANA LIFE SCIENCES LTD
Dexcom Appoints Renée Galá to Board of Directors
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025. Ms. Galá is an accomplished executive with significant financial, strategic and operational leadership experience across the life sciences sector. She currently serves as President and Chief Operating Officer of Jazz Pharmaceuticals Public Limited Company, a global biopharmaceutical company with greater than $4 billion in total revenues in 2024 whose purpose is to innovate to transform the lives of p...
Dexcom Announces Upcoming Conference Presentation
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that management will present an update on the company at the 46th Annual Raymond James Institutional Investors Conference on Tuesday, March 4th. The live presentation is scheduled to begin at approximately 10:25 AM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneere...
Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Revenue grew 8% year-over-year to $1.114 billion on a reported basis and 8% year-over-year on an organic1 basis. U.S. revenue grew 4% and international revenue grew 17% on a reported basis and 19% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $188.9 million or 17.0% of revenue, a decrease of 400 basis points compared to the fourth quarter of 2023. Non-...
Hain Celestial Reports Fiscal Second Quarter 2025 Financial Results
Hain Celestial Reports Fiscal Second Quarter 2025 Financial Results Strong Operating Cash Flow and Reduction in Debt; Positioned to Pivot to Growth in Back HalfExploring Strategic Options for Personal Care Category HOBOKEN, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Hain Celestial Group (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, today reported financial results for its fiscal second quarter ended December 31, 2024. “Despite challenges in the quarter, we generated strong operating cash flow and fur...
Dexcom Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release ...
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2024 financial results after market close on Thursday, February 13, 2025. Management will hold a conference call to review the company's fourth quarter and fiscal year 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at and will be archived there for future reference. To listen to the conference call, please dial (888) 4...
Hain Celestial Announces Fiscal Second Quarter 2025 Results Conference...
Hain Celestial Announces Fiscal Second Quarter 2025 Results Conference Call and Webcast HOBOKEN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Hain Celestial Group (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, plans to issue its financial results for the fiscal second quarter before the market opens on Monday, February 10, 2025. The company will host a conference call, which will be webcast, to discuss the results at 8:00 AM ET. Speaking on behalf of Hain Celestial will be Wendy Davidson, President and Ch...
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter a...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the fourth quarter of 2023. U.S. revenue is expected to be approximately $803 million, representing growth of 4% over the fourth quarter of 2023. International revenue is expected to be approximately $310 million, an increase of 17% over the fourth quarter of 2023. For fiscal 2024, total preliminary, unaudited revenue is approximately $4.032 billion, an increase of 11% over 2...
Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that management will present an update on the company at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025. The live presentation is scheduled to begin at approximately 12:00 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the sta...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.